HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has maintained a Neutral rating on Co-Diagnostics (NASDAQ:CODX) and lowered the price target from $3 to $2.
August 14, 2023 | 10:46 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Co-Diagnostics' price target has been lowered from $3 to $2 by HC Wainwright & Co. The firm maintains a Neutral rating on the stock.
The lowering of the price target by HC Wainwright & Co. indicates a less optimistic outlook for the stock, which could potentially lead to a decrease in its price in the short term. The maintained Neutral rating suggests that the firm does not see significant upside or downside from the current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100